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O steogenesis imperfecta (OI) is a heritable bone disorder that is manifested as various degrees 
of bone fragility.  A widely used clinical classiﬁcation 
of OI was proposed by Sillence in 1979 [1] and 
revised by van Dijk and Sillence in 2014 [2].  Most 
cases of OI are caused by genetic mutation of the type 
I collagen gene [3,4].  Type I collagen molecules are 
connected to one another by pyridinoline cross-links 
that contribute to increased strength and bone ﬂexibil-
ity.  The N-terminal telopeptide of type I collagen 
(NTx) is a peptide that includes a pyridinoline cross-
link.  NTx is excreted during bone resorption,  and the 
NTx levels in serum and urine can be measured.  
Urinary NTx (uNTx) reﬂects the state of bone resorp-
tion in various conditions,  such as postmenopausal 
osteoporosis and bone metastasis of cancer [5-7].  
Urinary NTx levels in healthy children and adoles-
cents are higher than those in adults and change 
according to the growth rate during childhood [8,9].
　 In an earlier study we compared the uNTx levels of 
children with OI with those of healthy children,  and 
Acta Med.  Okayama,  2016
Vol.  70,  No.  6,  pp.  435-439
CopyrightⒸ 2016 by Okayama University Medical School.
http ://escholarship.lib.okayama-u.ac.jp/amo/Original Article
Urinary Cross-linked N-terminal Telopeptide of Type I  
Collagen Levels of Infants with Osteogenesis  
Imperfecta and Healthy Infants
Miho Yamashitaa,  Kosei Hasegawaa＊,  Yousuke Higuchia,  Takayuki Miyaia,   
Ayumi Okadab,  Hiroyuki Tanakac,  and Hirokazu Tsukaharab
Department of Pediatrics,  aOkayama University Hospital,  and bOkayama University Graduate School of Medicine,   
Dentistry and Pharmaceutical Sciences,  Okayama 700-8558,  Japan,  cDepartment of Pediatrics,   
Okayama Saiseikai General Hospital,  Okayama 700-8511,  Japan
The urinary cross-linked N-terminal telopeptide of type I collagen (uNTx) levels in infantile osteogene-
sis imperfecta (OI) have not been well studied.  Here we investigated the levels of uNTx in infants with 
OI and healthy infants.  We collected spot urine samples from 30 infants with OI (male/female,  
14/16; Sillence classiﬁcation,  I/II/III/IV: 15/3/6/6; age,  5.2±4.4 months) and 120 healthy infants 
(male/female,  75/45; age,  5.1±4.1 months) for the measurement of uNTx levels.  The uNTx levels of 
the OI infants were signiﬁcantly lower than those of the healthy infants (mean±SD,  1,363.7±530.1 vs. 
2,622.2±1,202.6 nmol BCE/mmol Cr; p＜0.001).  The uNTx levels of the infants with type I OI were 
signiﬁcantly lower than those of the age-matched healthy infants,  although an overlap was observed 
between the 2 groups.  Among the 1-month-old infants,  the uNTx levels of the infants with types I,  III 
or IV OI were signiﬁcantly lower than those of the healthy infants,  without overlap (1,622.5±235.8 vs. 
3,781.0±1,027.1 nmol BCE/mmol Cr; p＜0.001).  These results indicate that uNTx levels are signiﬁ-
cantly lower in infants with OI than in healthy infants,  and they suggest that uNTx might be useful as 
a reference for diagnosing OI.
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our ﬁndings revealed that the uNTx levels of the chil-
dren with OI tended to be lower than those of the 
healthy children,  especially at a younger age [10].  
This ﬁnding conﬂicts with those of other studies in 
children and adult patients with OI,  which reported 
that bone resorption markers in OI are normal or 
slightly elevated compared with healthy age-matched 
controls [11-13].
　 In contrast to pediatric and adult patients with OI,  
the uNTx levels of infant OI patients have not been 
clariﬁed.  In the present study we analyzed the uNTx 
levels of infants with OI and healthy infants to deter-
mine whether the measurement of uNTx―which is 
done in a noninvasive examination―makes it possible 
to diﬀerentiate infants with OI from healthy infants.
Subjects and Methods
　 Subjects. Thirty infants with OI were included 
in this study.  For controls,  120 healthy infants who 
presented to a hospital in Okayama (latitude,  34° north) 
on the mainland of Japan,  which had 2,028.2 h of day-
light per year in 2011,  were also included.  The sub-
jectsʼ characteristics (age,  sex,  and OI type) are 
summarized in Table 1.  The distribution of ages was 
comparable between the groups (p＝0.85).
　 All 30 OI patients were clinically diagnosed with 
OI based on clinical features,  such as frequent bone 
fractures,  family history,  dentinogenesis imperfecta,  
and blue sclera.  All but one of the infants with OI 
suﬀered from one or more bone fractures 2-4 weeks 
before the collection of urine samples.  All of the 
infants with type II OI had experienced multiple frac-
tures before and after birth,  and they received 
mechanical ventilation.  All 120 of the healthy infants 
were born at term and had an appropriate weight for 
gestational age.  Most of the healthy infants and infants 
with OI,  except for the type II OI patients,  were 
breast-fed.  None of the subjects showed apparent 
renal impairment.  Informed consent was obtained from 
the parents or guardians of all infants included in this 
study.  This study was approved by the Ethics Com-
mittee of Okayama University Hospital (approval no. 
1454) and conducted according to the Declaration of 
Helsinki.
　 Urine sample collection and measurement of 
uNTx. Spot urine samples were collected from 
each infant after informed consent was obtained from 
the parent/guardian.  Urine samples were collected 
from the healthy infants at a random time during a 
medical checkup performed in the months from July to 
September (summer to early autumn) 2011.  The urine 
samples were collected from the infants with OI at a 
random time before the ﬁrst pamidronate infusion 
during any of the seasons: spring (March to May):  
n＝6,  summer (June to August): n＝7,  autumn 
(September to November): n＝9,  and winter 
(December to February): n＝8.  All urine samples 
were stored at －20 ℃ until analysis.  The levels of 
uNTx were measured by an enzyme-linked immunosor-
bent assay (ELISA) at the Life Science Institute 
(Tokyo,  Japan) using the Osteomark® NTx Urine 
Assay (Alere Scarborough,  Scarborough,  ME,  USA).  
The inter- and intra-assay coeﬃcients of variation 
were below 7-10 .  All uNTx assay results were 
corrected by the creatinine level in the urine (nmol 
BCE/mmol creatinine).
　 Statistics. All values are expressed as the 
mean±standard deviation (SD).  Statistical analyses 
were performed using the software program JMP 9.02 
(SAS Institute,  Cary,  NC,  USA).  A t-test was con-
ducted to evaluate the diﬀerences in values between 
the healthy infants and OI infants.  Diﬀerences were 
considered signiﬁcant at p＜0.05.
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Table 1　 Characteristics of the study subjects
Subjects Healthy infants
Infants with osteogenesis imperfecta
All Type I Type II Type III Type IV
Number 120 30 15 3 6 6
Age (month＊) 5.06±4.14 5.23±4.41 6.93±4.31 1.00±0.00 3.33±4.41 5.00±4.15
Sex (m/f) (75/45) (14/16) (7/8) (2/1) (2/4) (3/3)
＊Data areas mean±SD.
Results
　 Levels of uNTx in the healthy infants and 
infants with OI. The uNTx levels of the healthy 
infants and infants with OI are shown in Fig. 1.  The 
uNTx levels of the healthy infants tended to be higher 
at a younger age.  The comparison of the uNTx levels 
between the 2 groups revealed that the uNTx levels 
were signiﬁcantly lower in the infants with OI com-
pared to the age-matched healthy infants (1,363.7±
530.1 vs. 2,622.2±1,202.6; p＜0.001).  We re-ana-
lyzed the data,  excluding the infants with type II OI 
from the all-OI group,  taking into consideration the 
eﬀect of the extremely serious condition of type II OI 
on bone turnover.  When the 3 patients with type II OI 
were excluded (age of healthy infants: 5.1±4.1 
months; OI: 5.7±4.4 months,  p＝0.47),  the uNTx 
levels were still signiﬁcantly lower in the infants with 
OI compared to the healthy infants (1,444.0±488.1 
vs. 2,622.2±1,202.6; p＜0.001).
　 Comparison of uNTx levels in type I OI 
infants and age-matched healthy infants.
Because infants with type I OI,  the mildest form of OI,  
show only mild clinical features,  it is sometimes diﬃ-
cult to diagnose OI clinically.  We therefore compared 
the uNTx levels of the 15 infants with type I OI with 
those of the 79 age-matched healthy infants (age of 
type I patients 6.9±4.3 months; healthy infants 
6.8±4.0 months; p＝0.92) to determine whether the 
measurement of the uNTx level could diﬀerentiate 
infants with type I OI from healthy infants.
　 The results of the comparison demonstrated that 
the uNTx levels of the infants with type I OI were 
signiﬁcantly lower than those of the age-matched 
healthy infants,  but an overlap of values was observed 
between the 2 groups (1,504.6±553.8 vs. 2,218.2±
949.0; p＝0.006),  and it was diﬃcult to observe any 
clear diﬀerentiation by uNTx level between the infants 
with type I OI and the healthy infants.
　 Levels of uNTx at 1 month old. Lastly,  we 
analyzed the diﬀerence in uNTx levels between the OI 
and healthy infants at 1 month old.  The results are 
shown in Fig. 2.  For the reason described above,  we 
also excluded the infants with type II OI from this 
analysis.  The uNTx levels of the 1-month-old OI 
infants were signiﬁcantly lower than those of the 
same-age healthy infants (1,622.5±235.8 vs. 3,781.0
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Fig. 1　 Relationship between age and uNTx levels from 1 to 12 
months,  in the 120 healthy infants (A) (y＝2,746.9619－157.49x
＋50.01 [x－5.0667]2－5.2099 [x－5.07]3,  r＝－0.70,  p＜0.001) 
and the 30 infants with osteogenesis imperfecta (OI) (B).
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Fig. 2　 Urinary NTx levels in 1-month-old OI infants (total＝11;  
type I,  n＝3; type II,  n＝3; type IV,  n＝4; type III,  n＝1) and 
1-month-old healthy infants (n＝45).  ＊p＜0.001.
±1,027.1; p＜0.001).  No overlap in uNTx levels was 
observed between these 2 groups.
　 To analyze whether the body size of infants at 1 
month old aﬀects uNTx levels,  we analyzed the rela-
tion between uNTx levels and body height and between 
uNTx levels and body weight at each sample collec-
tion.  No signiﬁcant relationship between uNTx levels 
and height or body weight was demonstrated in the 44 
healthy infants and in the OI infants (Fig. 3A,  B).
Discussion
　 The results of the present study demonstrated for 
the ﬁrst time that the uNTx levels of infants with OI 
are signiﬁcantly lower compared to those of healthy 
infants.  uNTx reﬂects the amount of excreted pyrid-
inoline cross-links,  as well as the state of bone 
resorption.  The total amount of pyridinoline cross-
links per one collagen molecule in the bone of OI 
patients was reported to be equal to that of control 
bone [14].  Our present ﬁndings suggest that the lower 
uNTx levels in infants with OI are attributable to their 
lower bone mass.
　 We collected urine samples from the healthy 
infants in summer to early autumn in order to mini-
mize the eﬀects of vitamin D deﬁciency on bone turn-
over.  Most of the infants with OI and healthy infants 
in our study were breast-fed.  Breast-fed infants have 
lower serum 25-hydroxy vitamin D concentrations and 
signiﬁcantly increased intact parathyroid hormone 
levels compared to formula- or mixed-fed infants [15].  
In summer,  the prevalence of vitamin D deﬁciency is 
reduced and bone resorption is decreased compared 
with the other seasons.  Although uNTx levels are 
thought to be decreased in healthy infants,  we 
observed that the uNTx levels of the present studyʼs 
OI infants,  from whom urine was collected across all 
four seasons,  were signiﬁcantly lower than those of 
the healthy infants.
　 We also observed that,  among the 1-month-old sub-
jects,  the uNTx levels of the infants with OI were 
signiﬁcantly lower than those of the healthy infants,  
with no overlap of the NTx levels between the 2 
groups.  We attribute this ﬁnding to the diﬀerence in 
bone mass between the 2 groups and to the highest 
bone turnover state at this age [16].  Although the 
number of 1-month-old infants with OI that we ana-
lyzed in this study was small,  the uNTx levels at 1 
month old might become a good marker for diagnosing 
OI.
　 The limitations of our study are as follows.  (1) The 
eﬀects of bone fractures on the uNTx level are not 
known,  and (2) we were unable to collect blood sam-
ples from the subjects at the same time of urine sam-
ple collection and thus we could not measure serum 
25(OH) vitamin D levels,  parathyroid hormone levels 
or bone formation markers.  The uNTX level is 
aﬀected by vitamin D status,  parathyroid hormone 
levels and bone formation status [17].  To determine 
whether the uNTX level in a 1-month-old patient can 
be used as a diagnostic marker of OI,  these problems 
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Fig. 3　 Relationship between uNTx levels and the body height 
and body weight of 1-month-old healthy controls (n＝44) and 
infants with OI (n＝6).  In the healthy infants,  there was no signiﬁ-
cant relationship between uNTx levels and body height (A),  (r＝ 
－0.15,  p＝0.32) or body weight (B),  (r＝－0.008,  p＝0.96).  Also 
in the OI infants,  no signiﬁcant relationship between uNTX levels 
and body height (A) (r＝－0.12,  p＝0.40) or body weight (B) (r＝
0.06,  p＝0.65) was observed.
must be addressed.
　 In conclusion,  we observed that the uNTx levels of 
infants with OI were signiﬁcantly lower than those of 
healthy infants.  While additional studies are neces-
sary,  our present ﬁndings suggest that uNTx might be 
useful as a reference for diagnosing OI.
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